Be Ready.
When Minutes Matter®
INTERCEPT® Fibrinogen Complex is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life. IFC contains fibrinogen, factor XIII, von Willebrand factor and other key clotting factors which are required for clot strength and hemostasis in patients with massive hemorrhage associated with fibrinogen deficiency.1-4
The IFC Advantage
Transfuse Immediately*
When controlling hemorrhage, faster is better. 5-day post-thaw shelf life allows IFC to be thawed in advance and available for immediate, empirical use.
Control Bleeding†
IFC is an enriched source of key clotting constituents immediately available* to treat and control bleeding associated with fibrinogen deficiency.
Control Bleeding†
IFC is an enriched source of key clotting constituents immediately available* to treat and control bleeding associated with fibrinogen deficiency.
Protect Patients†
IFC provides broad spectrum transfusion transmitted infection (TTI) risk reduction by inactivating viruses, bacteria, protozoans, and leukocytes.6,7,**
How IFC Works
Be Ready.
When Minutes Matter®
You may also be interested in
What's in the bag?
When Minutes Matter. INTERCEPT Fibrinogen Complex is an enriched source of key constituents in effective homeostasis for the treatment and control of hemorrhage.
Clot Generation
Successfully regaining hemostasis during hemorrhage requires a complex balance of factors involved in clot initiation and construction.
Resources
View our resources area for package inserts and product information.
*INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; when stored frozen, requires thawing prior to use.
**There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to package Insert.
†Bleeding associated with fibrinogen deficiency.
References:
- Levy JH, Welsby I, et al. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014;54(5):1389-1405; quiz 1388.
- Schroeder V, Kohler HP. Factor XIII: Structure and Function. Seminars in Thrombosis and Hemostasis 2016;42(4):422-428.
- Peyvandi, F. Diagnosis and management of patients with von Willebrand’s disease in Italy: an Expert Meeting Report. Blood Transfusion 2018;16(4):326-328.
- Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood reviews 2015;29:17-24.
- Meyer DE, Vincent LE, Fox EE, et al. Every minute counts: Time to delivery of initial massive transfusion cooler and its impact on mortality. The journal of trauma and acute care surgery 2017;83:19-24.
- INTERCEPT Blood System for Plasma Package Insert.
- INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex Package Insert.